CenterBook Partners LP Takes Position in TransMedics Group, Inc. (NASDAQ:TMDX)

CenterBook Partners LP purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 8,369 shares of the company’s stock, valued at approximately $522,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Arizona State Retirement System lifted its stake in TransMedics Group by 1.9% in the fourth quarter. Arizona State Retirement System now owns 9,668 shares of the company’s stock valued at $603,000 after buying an additional 184 shares during the period. National Bank of Canada FI increased its stake in shares of TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after acquiring an additional 262 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its position in shares of TransMedics Group by 7.2% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company’s stock valued at $294,000 after acquiring an additional 317 shares during the period. Park Avenue Securities LLC boosted its stake in TransMedics Group by 3.8% during the 4th quarter. Park Avenue Securities LLC now owns 8,797 shares of the company’s stock worth $548,000 after acquiring an additional 322 shares during the last quarter. Finally, Captrust Financial Advisors boosted its stake in TransMedics Group by 20.6% during the 3rd quarter. Captrust Financial Advisors now owns 1,988 shares of the company’s stock worth $312,000 after acquiring an additional 340 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Price Performance

TMDX stock opened at $80.58 on Friday. The stock has a 50-day moving average price of $70.94 and a two-hundred day moving average price of $81.62. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The stock has a market cap of $2.71 billion, a PE ratio of 85.72 and a beta of 2.14. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on TMDX shares. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Canaccord Genuity Group restated a “buy” rating and issued a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Wednesday, March 26th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.